The Power List 2022 focuses on the top 10 VIPs in three key categories of medicine making
Voting is now open for the 2024 Company of the Year Awards
| 13 min read
What role must pharma play to help improve outcomes for women?
| 8 min read
The cell cycle can be used to shut down cancer’s survival mechanisms, but what does it take to turn that knowledge into a medicine?
| 6 min read
Two friends, two countries; one disease, one network to fight it. We spoke to two leaders of DNDi’s Leishmaniasis East Africa Network.
| 5 min read
Clinical trials? Cancer R&D? AstraZeneca’s Matthew Ellis shares his views on the future of pharma.
How pharma is working to develop efficient and patient-centric trials.
| 2 min read
A trial for a new immunotherapy is seeing incredible results for rectal cancer patients.
The war in Ukraine has massively impacted clinical trials. We spoke to one man tracking the disruption.
Clinical trials suffer from heavy dropout rates. Perhaps the answer is a little care and attention.
What is going on with Aduhelm? And why is the drug seen by some to be controversial?
A report from Clarivate has tipped 7 drugs for potential blockbuster status in 2022. Here’s what makes them stand out.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.
One Vaccine to Rule Them All
Uniting a Cell and Gene Kingdom
Cell Culture Media Is Big Business